Mary Kay Inc. Recommits to Responsible and Sustainable Water Management Following World Water Day 2022
Water is essential to life in all its forms and to the ongoing development of a healthy and sustainable future. According to the World Economic Forum, environmental risks and the impact on natural ecosystems and resources continues to be a top global risk.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005126/en/
Richard R. Rogers (R3) Manufacturing/R&D Center in Lewisville, Texas, U.S.A (Photo: Mary Kay Inc.)
This World Water Day, Mary Kay Inc. recommits to responsible and sustainable water management to ensure the ongoing availability of water as an essential resource to meet the needs of the environment and communities around the world.
Water is at the heart of Mary Kay’s sustainability strategy and crucial to its manufacturing processes. Implementing good water stewardship principles is critical for Mary Kay to reach our sustainability goals. We strive to ensure water use for human and economic needs does not disrupt sustainable water cycles or cause ongoing harm to nature and biodiversity. Recent water efforts at Mary Kay facilities include:
- Water use at U.S. Mary Kay-owned facilities decreased 36% from 2012-2017.
-
At Mary Kay’s manufacturing facility in Hangzhou, China, significant strides toward water conservation include:
- Reduced potable water use by 34%, which saves approximately 913,480 gallons of potable water per year.
- Reverse Osmosis (RO) reject water reuse: The purifying water equipment produces a large amount of concentrated water discharge in the operation process. By collecting concentrated water and passing it through the circulation system, concentrated water will be reused through the fire tower and air-cooling tower system as a supplementary water source.
- Wastewater treatment upgrade: To mitigate the environmental impact of wastewater in its manufacturing processes, Mary Kay China invested in an advanced membrane bioreactor (MBR) process using existing infrastructure to improve the capacity of wastewater treatment and reduce sludge discharge by 40%.
“As a global sustainability advocate, Mary Kay is dedicated to playing an important role in collective efforts to cause no harm to the environment and to ensure communities and economies prosper,” said Deborah Gibbins, Chief Operating Officer at Mary Kay Inc. “Mary Kay will continue to build upon its progress and work toward its commitment of reducing water utilization in our manufacturing processes by 30% by the year 2030 versus a 2020 baseline per kilogram bulk produced. Achieving Alliance for Water Stewardship (AWS) Core Certification for Mary Kay manufacturing facilities in the U.S. and China will help move us closer to our goals.”
Several key components of Mary Kay’s decade of action include:
- A current signatory of the UN Ocean Principles and CEO Water Mandate.
-
Continuing its 32-year partnership with The Nature Conservancy and supporting 11 global water projects in 2022 focusing on:
- Global ocean protection to improve ocean health for nature and people;
- Restoring Asia Pacific Shellfish Reefs in Australia, Hong Kong, China, the Coral Triangle, and the Cakaulevu Reef (also called the Great Sea Reef);
- Supporting Women Leaders in The Pacific in Papua New Guinea (Mangroves, Women, and Markets) and the Solomon Islands (Community Health and Resilience);
- Coastal Conservation and Restoration in the Gulf Coast (Protecting the Gulf Coast Coastal Wetlands);
- Improving Fisheries in Mexico (Improving Fisheries and Empowering Communities); and
- Collaborating with partners in Europe supporting native oyster restoration projects in England, Scotland, Ireland, France, the Netherlands, Germany, and Sweden.
- Joining Alliance for Water Stewardship and working to achieve certification of our two manufacturing facilities by 2025.
To read more about Mary Kay’s commitment to sustainability, visit marykayglobal.com/sustainability and download Mary Kay’s global sustainability strategy, Enriching Lives Today for a Sustainable Tomorrow.
About Mary Kay Inc.
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
About The Nature Conservancy
The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005126/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
